Implantica AG (OSTO:IMP A SDB) Change In Receivables : kr0.00 Mil (TTM As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Change In Receivables?

Implantica AG's change in receivables for the quarter that ended in . 20 was kr0.00 Mil. It means Implantica AG's Accounts Receivable stayed the same from . 20 to . 20 .

Implantica AG's change in receivables for the fiscal year that ended in . 20 was kr0.00 Mil. It means Implantica AG's Accounts Receivable stayed the same from . 20 to . 20 .

Implantica AG's Accounts Receivable for the quarter that ended in . 20 was kr0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Implantica AG's liquidation value for the six months ended in . 20 was kr0.00 Mil.

Implantica AG Change In Receivables Historical Data

The historical data trend for Implantica AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Change In Receivables Chart

Implantica AG Annual Data

Trend

Change In Receivables

Implantica AG Semi-Annual Data

Change In Receivables

Implantica AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in . 20 was kr0.00 Mil.

Implantica AG (OSTO:IMP A SDB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Implantica AG's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=		/		*	91
=

2. In Ben Graham's calculation of liquidation value, Implantica AG's accounts receivable are only considered to be worth 75% of book value:

Implantica AG's liquidation value for the quarter that ended in . 20 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=		-		+	0.75 *	+	0.5 *
=	0.00

Implantica AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Implantica AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Implantica AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

8IM1:Germany

Address

Aeulestrasse 45, Vaduz, LIE, 9490

Website

https://www.implantica.com

Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines